4 results
-To answer the main question *Can we demonstrate a decreased prevalence of fatigue (i.e. a lower score on the fatigue assessment) in patients in complete remission after successful treatment of a gynaecological malignancy, after treatment of a…
The present proposal seeks to compare the cardiovascular and gastrointestinal safety and effectiveness of a strategy of initial randomisation to treatment with the selective COX-2 inhibitor celecoxib or to *usual-care* with their current non-…
To measure in vivo effect on neuroinflammation of treatment with celecoxib, a selective COX-2 inhibitor, in PD using PK111-95 and PET.Celecoxib showed broad utility in animal models of neurodegeneration. Neurochemical effect of the treatment on…
Primary Objectives* To evaluate the efficacy of SCY-078 as determined by a Data Monitoring Committee(DMC) by assessing global success (composite assessment of clinical and mycologicalsuccess) at EoT* To evaluate the safety of SCY-078